Yunjoo Cho

Yunjoo Cho

Auto-generated profile, based on publicly available information

Yunjoo Cho

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
YCYunjoo Cho
Yunjoo Cho
SASoomin Ahn
Soomin Ahn
KKKyoung-Mee Kim
Kyoung-Mee Kim
Cho Y, et al. J Gastric Cancer. 2024 Dec;25:e4. https://doi.org/10.5230/jgc.2025.25.e4

15 September 2021 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
JLJiyeon Lee
Jiyeon Lee
YCYunjoo Cho
Yunjoo Cho
KCKyue Hee Choi
Kyue Hee Choi
IHInwoo Hwang
Inwoo Hwang
YOYoung Lyun Oh
Young Lyun Oh
Metastatic leiomyosarcoma to the thyroid is an extremely rare occurrence, and only 18 cases have been reported. Here, we report a case of a 37-year-old woman who presented with multiple masses on the scalp. Excisional biopsy was done and the mass revealed fascicles of smooth muscle fibers which showed positive staining for smooth muscle actin, thus confirming the diagnosis of leiomyosarcoma. The patient was also found to have a 0.9 cm mass within the left thyroid. Fine-needle aspiration was done and the cytological smear showed hypercellular spindle cell clusters with hyperchromatic and large nuclei. Normal thyroid follicular cells were found within or around tumor cells. In this report, we present the cytologic findings of metastatic leiomyosarcoma to the thyroid and offer differential diagnoses of the aspirated spindle cells.

15 January 2024 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
YCYunjoo Cho
Yunjoo Cho
JLJiyeon Lee
Jiyeon Lee
BHBogyeong Han
Bogyeong Han
SYSang Eun Yoon
Sang Eun Yoon
SKSeok Jin Kim
Seok Jin Kim
JCJunhun Cho
Junhun Cho
Background: The implication of the presence of tumor-infiltrating T lymphocytes (TIL-T) in diffuse large B-cell lymphoma (DLBCL) is yet to be elucidated. We aimed to investigate the effect of TIL-T levels on the prognosis of patients with DLBCL.Methods: Ninety-six patients with DLBCL were enrolled in the study. The TIL-T ratio was measured using QuPath, a digital pathology software package. The TIL-T ratio was investigated in three foci (highest, intermediate, and lowest) for each case, resulting in TIL-T–Max, TIL-T–Intermediate, and TIL-T–Min. The relationship between the TIL-T ratios and prognosis was investigated.Results: When 19% was used as the cutoff value for TIL-T–Max, 72 (75.0%) and 24 (25.0%) patients had high and low TIL-T–Max, respectively. A high TIL-T–Max was significantly associated with lower serum lactate dehydrogenase levels (p < .001), with patient group who achieved complete remission after RCHOP therapy (p < .001), and a low-risk revised International Prognostic Index score (p < .001). Univariate analysis showed that patients with a low TIL-T–Max had a significantly worse prognosis in overall survival compared to those with a high TIL-T–Max (p < .001); this difference remained significant in a multivariate analysis with Cox proportional hazards (hazard ratio, 7.55; 95% confidence interval, 2.54 to 22.42; p < .001).Conclusions: Patients with DLBCL with a high TIL-T–Max showed significantly better prognosis than those with a low TIL-T–Max, and the TIL-T–Max was an independent indicator of overall survival. These results suggest that evaluating TIL-T ratios using a digital pathology system is useful in predicting the prognosis of patients with DLBCL.

19 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
SASoomin Ahn
Soomin Ahn
IHInwoo Hwang
Inwoo Hwang
YKYuyeon Kim
Yuyeon Kim
SLSomin Lee
Somin Lee
YCYunjoo Cho
Yunjoo Cho
KKKyoung-Mee Kim
Kyoung-Mee Kim
Programmed death-ligand 1 (PD-L1) biomarker testing in gastric cancer is required to identify patients suitable for immunotherapy. However, the PD-L1 testing landscape is complex, with various PD-L1 tests available and multiple algorithms that combine tumor and immune cell staining. To provide guidance on the best practices for PD-L1 testing in gastric cancer, we reviewed the literature and incorporated our extensive experience using the PD-L1 IHC PharmDx 22C3 and 28-8 assays and scoring with the combined positive score (CPS) algorithm. This review summarizes inter-reader agreement and PD-L1 assay concordance studies in gastric cancer, highlights practical challenges and pitfalls encountered in our own laboratory, and proposes solutions to address them. Accurate and consistent interpretation of PD-L1 CPS in gastric cancer is challenging, but can be improved with training, experience, and close attention to interpretation guidelines. Techniques are available that can optimize the automated staining of PharmDx PD-L1 assays using the Autostainer Link 48 to ensure consistent staining performance. The PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 assays show high concordance when used according to manufacturers’ guidelines.